Open AccessANTIHIV/AIDS DRUG 6HP: ANTIVIRAL ACTIVITY, PRE-CLINICAL STUDY. EFFICIENCY IN ADULT HIV-INFECTED PATIENTS
Author(s) -
Г. А. Галегов,
В. Л. Андронова
Publication year - 2019
Publication title -
voprosy virusologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.151
H-Index - 15
eISSN - 2411-2097
pISSN - 0507-4088
DOI - 10.18821/0507-4088-2019-64-1-12-15
Subject(s) - tolerability , drug , antiretroviral drug , medicine , human immunodeficiency virus (hiv) , pharmacokinetics , zidovudine , pharmacology , in vivo , lamivudine , clinical trial , antiretroviral therapy , virology , immunology , viral load , biology , viral disease , adverse effect , virus , microbiology and biotechnology , hepatitis b virus
The new domestic antiretroviral drug 6HP, which is ammonium-3’-azido-3’-deoxythymidine-5’-carbomoylphosphonate, shows a high level of anti-HIV activity in cultures of lymphoblastoid cells. In a organism, the 6HP is converted to azidothymidine, and the its pharmacokinetic parameters indicate a prolonged nature of action of this compound in vivo. It is an important indicator that allows to formulate optimal therapeutic regimens during clinical application of 6HP. The complex of its antiviral properties and the results of its exhaustive preclinica study, as well as the results of studying its safety and tolerability in adult HIV-infected patients, including important first data of its use as a specific therapeutic anti-HIV / AIDS drug, certainly indicate on its prospects and its usefulness in clinical use in patients with HIV infection, including as part of combination antiretroviral therapy.